Abstract: The present disclosure provides pharmaceutical compositions for monoclonal antibodies, antibody-related products, therapeutic proteins, peptides and other biopharmaceuticals. The compositions provide initial and long term stability of the biopharmaceutical agent, rendering them suitable for parenteral, pulmonary, transdermal, topical, intradermal, intrascleral, intracorneal, ocular and other forms of delivery. The compositions and methods lead to higher yields in dilute solutions and reduce unwanted aggregation of the biopharmaceutical agent. The compositions and methods also allow for disaggregation of previously aggregated proteins and protection from aggregation upon dilution. Additionally, provided are non-aggregating antibody reagents for analytical immunoassays including ELISA methods. The invention provides compositions and methods for topical, enteral, parenteral, pulmonary and other forms of delivery of biologically active substances.

Abstract: The present disclosure provides pharmaceutical compositions for monoclonal antibodies, antibody-related products, therapeutic proteins, peptides and other biopharmaceuticals. The compositions provide initial and long term stability of the biopharmaceutical agent, rendering them suitable for parenteral, pulmonary, transdermal, topical, intradermal, intrascleral, intracorneal, ocular and other forms of delivery. The compositions and methods lead to higher yields in dilute solutions and reduce unwanted aggregation of the biopharmaceutical agent. The compositions and methods also allow for disaggregation of previously aggregated proteins and protection from aggregation upon dilution. Additionally, provided are non-aggregating antibody reagents for analytical immunoassays including ELISA methods. The invention provides compositions and methods for topical, enteral, parenteral, pulmonary and other forms of delivery of biologically active substances.

Abstract: A delivery mechanism and device for the passive periodic release of a drug or an active ingredient which avoids the need for external power sources and/or electronic controllers. By taking advantage of oscillating chemical systems, one can change the state, i.e. the pH, of a solution, a drug, enhancer or solubilizer resulting in oscillating the ability of an active ingredient to be delivered transdermally. The pH of a solution can be oscillated over a range of pH values from 2 to 10 by the reduction and oxidation (redox) reactions of salts, such as permanganates, iodates, sulfates, chlorates, or bromates. Upon activation, the delivery system conditions begin to oscillate and with it, the delivery of the active agent oscillates.